'Er pr' presentation slideshows

Adjuvante Systeemtherapie Borstkanker

855 views • 85 slides

Howard A. Burris III, MD, FACP Chief Medical Officer and Director of Drug Development

Managing HER2- Positive Breast Cancer in the Metastatic Setting: The Evolution of Targeted Therapies. Howard A. Burris III, MD, FACP Chief Medical Officer and Director of Drug Development Sarah Cannon Research Institute Memphis, TN Lee Schwartzberg, MD Medical Director, West Clinic

880 views • 70 slides

METASTATIC & Recurrent BREAST CANCER

Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center www.cccancer.com Wichita, KS - USA. METASTATIC & Recurrent BREAST CANCER. The Enormous Impact of Breast Cancer. 192,370 New Cases. 40,170 Deaths. 4% Melanoma of skin 4% Thyroid 27% Breast 15% Lung & bronchus

785 views • 50 slides

Updates on Breast Diseases: What clinicians need to know from pathologists

Updates on Breast Diseases: What clinicians need to know from pathologists. Preah Bat Norodom Sihanouk Hopsital, 22 April 2009 Monirath Hav, MD, Ph.D. fellow (VLIR project) Pathology Department, Ghent University Hospital Ghent University, Belgium. Benign breast lesions.

762 views • 50 slides

Management choices in breast cancer: maximizing survival with Xeloda

Management choices in breast cancer: maximizing survival with Xeloda. Laura Biganzoli Sandro Pitigliani Medical Oncology Unit Hospital of Prato Prato, Italy Andrew Wardley Christie Hospital and South Manchester University Hospital Manchester, UK. Clinical case history 1.

519 views • 33 slides

Amila Orucevic, MD, PhD Associate Professor, Director of Research Department of Pathology

362 views • 28 slides

Multiple Feedings of the Mind- Palliative Care Pearls

Multiple Feedings of the Mind- Palliative Care Pearls. Department of Medicine Grand Rounds January 29, 2010. Case. JG is a 32 year old woman who presented to JMC in 2001 (at the age of 23) with an an enlarging right sided breast mass.

265 views • 26 slides

X-tending the horizons of Xeloda into early breast cancer (BC)

X-tending the horizons of Xeloda into early breast cancer (BC). Wolfgang Janni Ludwig Maximilians University of Munich Munich, Germany. Rationale for integrating Xeloda into the treatment of early BC. High single-agent efficacy in metastatic BC

254 views • 16 slides

Breast cancer Not a single disease. Type and stage. Grade/Lympho-vascular invasion

Breast cancer Not a single disease. Type and stage. Grade/Lympho-vascular invasion Molecular biology. ERPR Her-2-neu Other. Gene expression profiling. (Tumor and Patient). What causes cancer? DNA damage. WHY? Always! Radiation, random, metabolic, toxins.

238 views • 13 slides

Breast cancer Not a single disease. Type and stage. Grade/Lympho-vascular invasion

Breast cancer Not a single disease. Type and stage. Grade/Lympho-vascular invasion Molecular biology. ERPR Her-2-neu Other. Gene expression profiling. (Tumor and Patient). What causes cancer? DNA damage. WHY? Always! Radiation, random, metabolic, toxins.

250 views • 13 slides

Geonomics in Breast Cancer

Geonomics in Breast Cancer. Decoding Human Genome Luis Barreras , M.D., FACP. Breast Cancer Figures. 1 in 8 women will develop breast cancer in their lifetime 180,000 women and 2,000 men yearly will develop breast cancer Over 40,000 women and men will die from breast cancer in 2009

246 views • 10 slides

HNC or HND in Computing Courses Benefits in Edinburgh

There are a few things you really need to do if you want a good career in IT industry and a course in HNC Computing in Edinburgh is one of those things.

100 views • 9 slides

Methods

Hormone receptor @ grade 2. double pos. % of patients. ER+ PR+ HER2-. Methods. triple pos. ER+ PR+ HER2+. Estrogen positive. Estrogen negative. Metabolic phenotype of HER2 +/- grade 2 tumors. Results. 241.1024 M-15. %. 147.0657. 257.1409 M+H. then: CI_GCT.

218 views • 5 slides